An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

Objective Metabolic reprogramming plays a critical role in modulating the innate and adaptive immune response, but its role ...

A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

Lupus is a chronic disease that can cause inflammation and pain in any part of the body. It’s an autoimmune disease, which ...

Researchers identified a key protein as a potential therapeutic target for stopping the body's immune system from mistakenly attacking itself, offering new hope for treating autoimmune diseases and ...

EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

Cutaneous lupus erythematosus is associated with an increased risk for ASCVD, similar to the risk seen in association with SLE.

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

Systemic lupus erythematosus is associated with substantial morbidity and involves major organs including the kidneys and the CNS. Based on randomized, controlled trials and long-term ...

Individuals with cutaneous lupus erythematosus have an increased ASCVD risk when compared with those without cutaneous lupus erythematosus.

Researchers have found that pregnant women with systemic lupus erythematosus (SLE) are at highly significantly increased risk ...